ADMA
ADMA Biologics Inc
9.50$
-1.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 78.4% | 78.1% | 78.8% | 80.7% | 81.5% | 67.8% | 68.9% | 71.6% | 70.8% | 74.7% | 76.8% | 77.2% | |
| 21.2% | 15.6% | 12.9% | 23.4% | 22.2% | 21.1% | 14.0% | 16.2% | 10.8% | 14.0% | 20.8% | 19.9% | |
| 21.2% | 15.6% | 12.9% | 23.4% | 22.2% | 21.1% | 14.0% | 16.2% | 10.8% | 14.0% | 20.8% | 19.9% | |
| 9.0% | 8.3% | 14.1% | 8.0% | 12.8% | 10.2% | 19.5% | 19.7% | 24.2% | 25.4% | 20.4% | 20.2% | |
| 46.7% | 52.5% | 50.7% | 47.8% | 44.0% | 34.8% | 33.7% | 34.3% | 34.6% | 33.1% | 33.4% | 35.0% | |
| 1.0% | 1.1% | 1.0% | 0.9% | 0.9% | 0.7% | 0.7% | 0.6% | 0.6% | 0.6% | 0.5% | 0.5% | |
| 0.1% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | |
| 56.6% | 58.9% | 56.2% | 50.0% | 40.6% | 28.6% | 26.9% | 28.7% | 24.2% | 23.5% | 41.3% | 40.3% | |
| 12.0% | 15.1% | 15.1% | 11.7% | 11.5% | 11.4% | 10.5% | 13.4% | 9.9% | 11.1% | 11.1% | 11.1% | |
| 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.6% | 0.6% | 0.7% | 0.7% | |
| 3.1% | 4.8% | 4.9% | 3.8% | 4.1% | 4.1% | 4.0% | 5.3% | 4.2% | 3.6% | 3.1% | 4.6% | |
| 40.7% | 39.7% | 37.3% | 34.8% | 25.9% | 14.8% | 14.2% | 13.1% | 12.3% | 11.1% | 29.1% | 28.2% | |
| 43.4% | 41.1% | 43.8% | 50.0% | 59.4% | 71.4% | 73.1% | 71.3% | 75.8% | 76.5% | 58.7% | 59.7% | |
| -140.0% | -153.8% | -139.2% | -121.3% | -107.6% | -63.1% | -55.2% | -44.3% | -37.1% | -25.9% | -17.5% | -11.5% | |
| 67.0% | 68.6% | 67.4% | 64.3% | 62.7% | 50.3% | 47.9% | 44.5% | 43.0% | 39.1% | 36.1% | 33.7% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.